THE BE T
Multimedia Highlights
From the CardioSource WorldNews YouTube Channel | Scan the QR code to watch the full video
Add ‘Em Up: Risk Factor Control
Improves Survival
CRT for Mild Heart Failure: Can It Be
REVERSEd?
Myocardial Injury After TAVR: What
Matters, What Doesn’t?
Bittner V, Bertolet M, Barraza F, et al.
J Am Coll Cardiol. 2015;66(7):765-73.
Gold MR, Padhiar Am, Mealing S, et al.
JCHF. 2015;3(9):691-700.
Paradis J-M, Mania HS, Lasala JM, et al.
J Am Coll Cardiol Intv. 2015;8(11):1468-79.
Post-marketing Assessment of Major
Bleeding with Rivaroxaban
Phase 2 Trial Results of Single-dose
Gene Therapy for HF
Gene/Environment Interactions in
DCM: The MOGE(S) Classification
System
Michael E. Farkouh, MD: “The bottom line is
that patients who are initially randomized to an
optimal medical therapy arm alone do just as
well as those who have revascularization when
they are the BARI 2D population, who are relatively very stable patients. […] One of the main
messages of the BARI 2D trial is that we have to
optimize medical therapy.”
W. Frank Peacock, IV, MD: “Anticoagulants, by
definition, make you bleed; that’s the risk you
take. But when your risk of stroke is 20% and
your risk of having a fatal bleeding event is less
than 1%, this is easy math.”
Tamayo S, Patel M, Yuan Z, et al. J Am
Coll Cardiol. 2015;65(10_S):doi:10.1016/
S0735-1097(15)60281-9.
16
CardioSource WorldNews
Michael R. Gold, MD, PhD: “[At the 5-year follow up of the REVERSEd study,] patients who
received cardiac resynchronization therapy
[CRT] lived, on average, almost 2.5 years longer
by having CRT on versus off. […] And having a
CRT defibrillator prolonged life almost 3 years
compared to a CRT pacemaker.”
Jack W. Reich, MD: “In terms of episodes of
hospitalization for heart failure, the gene-therapy
treated patients, as a group, all of them, showed
a 67% decrease compared with placebo in
episodes of hospitalization for heart failure. And,
likewise, in mortality, the placebo group in the
first year showed a 7.1% mortality in heart failure.
[…] But in the gene-therapy treated patients,
there were no deaths from heart failure.”
Lars Svensson, MD: “The words of wisdom
are: be very careful with a big calcium load and
look at the coronary arteries as far as the height
above the leaflet—and that we’ve known for a
long time. I think the way we do the S3 now with
a more slow inflation, checking the position very
carefully, is a factor. We’ve seen the incidence
of root rupture go down now that we don’t do a
rapid deployment.”
Stephane Heymans, MD: “A lot of centers mainly
focus on the genes and gene mutations. And
in our cohort, about 30% of the patients have
indeed a clear familial context that, in about
10-20%, we can find a causal gene mutation. But
there is still this gap of 80% where other triggers—environmental factors or epigenetics—are
influencing the phenotype of a dilated cardiomyopathy.”
Hazebroek MR, Moors S, Dennert R, et al.
J Am Coll Cardiol. 2015;66(12):1313-23.
October 2015